Fluent Raises $2M for Thought-to-Speech Brain-Chip Technology

Melbourne-based Fluent, a pioneering brain-computer interface company spun out of the University of Melbourne, has successfully closed a $2 million funding round. This capital infusion is earmarked to advance its groundbreaking technology, which aims to translate silent thoughts into audible speech for individuals experiencing communication impairments due to neurological conditions. The innovative approach bypasses the need for highly invasive cranial surgery, positioning Fluent as a potentially more accessible solution in the neurotech space.

The pre-seed investment was a collaborative effort, drawing support from a diverse group of investors. Key participants include the University of Melbourne's Genesis Pre-Seed Fund, Pacific Channel, Galileo Ventures, Multiple Sclerosis WA, and prominent individuals such as paediatric audiologist Professor David Graydon. International backing came from New York's Jumpspace Ventures and London's Founder’s Factory, underscoring the global interest in Fluent's transformative potential.

Fluent's core innovation lies in a minimally invasive device designed to be placed beneath the scalp, resting above the brain's motor cortex – the region governing speech muscle control. Utilizing sophisticated machine learning algorithms, the system deciphers neural signals associated with intended speech, converting them into text or synthesized audio. This method offers a significant advantage over existing brain-computer interfaces that often require electrodes implanted directly within the skull, a procedure associated with higher risks and complexity.

Dr. Tim Mahoney, co-founder and biomedical engineer at Fluent, likens the technology's signal processing to deciphering unique 'QR codes' generated by the brain. "When a person speaks, distinct neural patterns emerge from the motor cortex corresponding to specific mouth and jaw movements," Dr. Mahoney explained. "Our device captures these sequential patterns, even when an individual with speech impairment attempts to vocalize, enabling us to interpret their intended message." This analogy highlights the precision and pattern-recognition capabilities central to Fluent's platform.

Preliminary human trials conducted at St Vincent’s Hospital Melbourne have validated the efficacy of Fluent's non-invasive electrode placement. These studies demonstrated that signal quality captured externally is comparable to that achieved with internal implants. The research involved participants speaking, miming, and imagining phrases while their brain activity was recorded. The subsequent development, leveraging extensive English-language neural datasets and a significant collaboration with a Japanese research team, has shown remarkable accuracy. A model developed by Fluent demonstrated the ability to correctly identify intended phrases from a pool of 128 options with 96% accuracy.

The University of Melbourne has been instrumental in nurturing Fluent from its inception. The company benefited from the university's innovation ecosystem, receiving initial Proof of Concept funding and guidance through the Melbourne Entrepreneurial Centre's accelerator program. This latest investment is expected to propel Fluent towards human clinical trials, a critical step in bringing this life-changing technology to market. The broader medtech sector, particularly in neurotechnology and assistive communication, is watching closely as Fluent aims to redefine possibilities for those affected by conditions like motor neurone disease and multiple sclerosis.